nach oben

Erschienen in:

08.08.2023

The strict regulation of HIF-1α by non-coding RNAs: new insight towards proliferation, metastasis, and therapeutic resistance strategies

verfasst von: Sabrean Farhan Jawad, Farag M. A. Altalbawy, Radhwan M. Hussein, Ali Abdulhussain Fadhil, Mohammed Abed Jawad, Rahman S. Zabibah, Tasneem Younus Taraki, Chakrabhavi Dhananjaya Mohan, Kanchugarakoppal S. Rangappa

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Abstract

The hypoxic environment is prominently witnessed in most solid tumors and is associated with the promotion of cell proliferation, epithelial-mesenchymal transition (EMT), angiogenesis, metabolic reprogramming, therapeutic resistance, and metastasis of tumor cells. All the effects are mediated by the expression of a transcription factor hypoxia-inducible factor-1α (HIF-1α). HIF-1α transcriptionally modulates the expression of genes responsible for all the aforementioned functions. The stability of HIF-1α is regulated by many proteins and non-coding RNAs (ncRNAs). In this article, we have critically discussed the crucial role of ncRNAs [such as microRNAs (miRNAs), long non-coding RNAs (lncRNAs), circular RNAs (circRNAs), Piwi-interacting RNAs (piRNAs), and transfer RNA (tRNA)-derived small RNAs (tsRNAs)] in the regulation of stability and expression of HIF-1α. We have comprehensively discussed the molecular mechanisms and relationship of HIF-1α with each type of ncRNA in either promotion or repression of human cancers and therapeutic resistance. We have also elaborated on ncRNAs that are in clinical examination for the treatment of cancers. Overall, the majority of aspects concerning the relationship between HIF-1α and ncRNAs have been discussed in this article.

Sin, S. Q., Mohan, C. D., Goh, R. M. W.-J., You, M., Nayak, S. C., Chen, L., et al. (2022). Hypoxia signaling in hepatocellular carcinoma: Challenges and therapeutic opportunities. Cancer and Metastasis Reviews. https://doi.org/10.1007/s10555-022-10071-1

Vaupel, P., & Harrison, L. (2004). Tumor Hypoxia: Causative Factors, Compensatory Mechanisms, and Cellular Response. The Oncologist, 9(S5), 4–9. https://doi.org/10.1634/theoncologist.9-90005-4CrossRefPubMed

Semenza, G. L. (2000). Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. Critical Reviews in Biochemistry and Molecular Biology, 35(2), 71–103. https://doi.org/10.1080/10409230091169186CrossRefPubMed

Muz, B., de la Puente, P., Azab, F., & Azab, A. K. (2015). The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy. Hypoxia (Auckl), 3, 83–92. https://doi.org/10.2147/hp.s93413CrossRefPubMed

Vaupel, P., Thews, O., & Hoeckel, M. (2001). Treatment resistance of solid tumors: role of hypoxia and anemia. Medical Oncology, 18(4), 243–259. https://doi.org/10.1385/mo:18:4:243CrossRefPubMed

Erler, J. T., Cawthorne, C. J., Williams, K. J., Koritzinsky, M., Wouters, B. G., Wilson, C., et al. (2004). Hypoxia-Mediated Down-Regulation of Bid and Bax in Tumors Occurs via Hypoxia-Inducible Factor 1-Dependent and -Independent Mechanisms and Contributes to Drug Resistance. Molecular and Cellular Biology, 24(7), 2875–2889. https://doi.org/10.1128/MCB.24.7.2875-2889.2004CrossRefPubMedPubMedCentral

Pennacchietti, S., Michieli, P., Galluzzo, M., Mazzone, M., Giordano, S., & Comoglio, P. M. (2003). Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell, 3(4), 347–361. https://doi.org/10.1016/S1535-6108(03)00085-0CrossRefPubMed

Graham, A. M., & Presnell, J. S. (2017). Hypoxia Inducible Factor (HIF) transcription factor family expansion, diversification, divergence and selection in eukaryotes. PLoS One, 12(6), e0179545. https://doi.org/10.1371/journal.pone.0179545CrossRefPubMedPubMedCentral

Palazon, A., Goldrath, A. W., Nizet, V., & Johnson, R. S. (2014). HIF transcription factors, inflammation, and immunity. Immunity, 41(4), 518–528. https://doi.org/10.1016/j.immuni.2014.09.008CrossRefPubMedPubMedCentral

10.

Cavadas, M. A. S., Nguyen, L. K., & Cheong, A. (2013). Hypoxia-inducible factor (HIF) network: insights from mathematical models. Cell Communication and Signaling: CCS, 11(1), 42. https://doi.org/10.1186/1478-811X-11-42CrossRefPubMedPubMedCentral

11.

McNeill, L. A., Hewitson, K. S., Claridge, T. D., Seibel, J. F., Horsfall, L. E., & Schofield, C. J. (2002). Hypoxia-inducible factor asparaginyl hydroxylase (FIH-1) catalyses hydroxylation at the β-carbon of asparagine-803. Biochemical Journal, 367(3), 571–575.CrossRefPubMedPubMedCentral

12.

Lando, D., Peet, D. J., Whelan, D. A., Gorman, J. J., & Whitelaw, M. L. (2002). Asparagine hydroxylation of the HIF transactivation domain: a hypoxic switch. Science, 295(5556), 858–861.CrossRefPubMed

13.

Mahon, P. C., Hirota, K., & Semenza, G. L. (2001). FIH-1: a novel protein that interacts with HIF-1α and VHL to mediate repression of HIF-1 transcriptional activity. Genes & Development, 15(20), 2675–2686.CrossRef

14.

Hashimoto, T., & Shibasaki, F. (2015). Hypoxia-Inducible Factor as an Angiogenic Master Switch. Frontiers in Pediatrics, 3. https://doi.org/10.3389/fped.2015.00033

15.

Cheng, L., Yu, H., Yan, N., Lai, K., & Xiang, M. (2017). Hypoxia-Inducible Factor-1α Target Genes Contribute to Retinal Neuroprotection. Frontiers in Cellular Neuroscience, 11. https://doi.org/10.3389/fncel.2017.00020

16.

Wang, X., Du, Z. W., Xu, T. M., Wang, X. J., Li, W., Gao, J. L., et al. (2021). HIF-1α Is a Rational Target for Future Ovarian Cancer Therapies. Frontiers in Oncology, 11, 785111. https://doi.org/10.3389/fonc.2021.785111CrossRefPubMedPubMedCentral

17.

Korbecki, J., Simińska, D., Gąssowska-Dobrowolska, M., Listos, J., Gutowska, I., Chlubek, D., et al. (2021). Chronic and Cycling Hypoxia: Drivers of Cancer Chronic Inflammation through HIF-1 and NF-κB Activation: A Review of the Molecular Mechanisms. International Journal of Molecular Sciences, 22(19). https://doi.org/10.3390/ijms221910701

18.

Tan, P., Wang, M., Zhong, A., Wang, Y., Du, J., Wang, J., et al. (2021). SRT1720 inhibits the growth of bladder cancer in organoids and murine models through the SIRT1-HIF axis. Oncogene, 40(42), 6081–6092. https://doi.org/10.1038/s41388-021-01999-9CrossRefPubMed

19.

Nelson, J. K., Thin, M. Z., Evan, T., Howell, S., Wu, M., Almeida, B., et al. (2022). USP25 promotes pathological HIF-1-driven metabolic reprogramming and is a potential therapeutic target in pancreatic cancer. Nature Communications, 13(1), 2070. https://doi.org/10.1038/s41467-022-29684-9CrossRefPubMedPubMedCentral

20.

Bian, Y., Yin, G., Wang, G., Liu, T., Liang, L., Yang, X., et al. (2022). Degradation of HIF-1α induced by curcumol blocks glutaminolysis and inhibits epithelial-mesenchymal transition and invasion in colorectal cancer cells. Cell Biology and Toxicology. https://doi.org/10.1007/s10565-021-09681-2

21.

Kishore, C., & Karunagaran, D. (2022). Non-coding RNAs as emerging regulators and biomarkers in colorectal cancer. Molecular and Cellular Biochemistry, 477(6), 1817–1828. https://doi.org/10.1007/s11010-022-04412-5CrossRefPubMed

22.

Ashrafizadeh, M., Mohan, C. D., Rangappa, S., Zarrabi, A., Hushmandi, K., Kumar, A. P., et al. (2023). Noncoding RNAs as regulators of STAT3 pathway in gastrointestinal cancers: Roles in cancer progression and therapeutic response. Medicinal Research Reviews. https://doi.org/10.1002/med.21950

23.

Uchino, K., Ochiya, T., & Takeshita, F. (2013). RNAi therapeutics and applications of microRNAs in cancer treatment. Japanese Journal of Clinical Oncology, 43(6), 596–607. https://doi.org/10.1093/jjco/hyt052CrossRefPubMed

24.

Wang, Z., Rao, D. D., Senzer, N., & Nemunaitis, J. (2011). RNA interference and cancer therapy. Pharmaceutical Research, 28(12), 2983–2995. https://doi.org/10.1007/s11095-011-0604-5CrossRefPubMed

25.

O'Brien, J., Hayder, H., Zayed, Y., & Peng, C. (2018). Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation. Frontiers in Endocrinology, 9. https://doi.org/10.3389/fendo.2018.00402

26.

Tay, Y., Zhang, J., Thomson, A. M., Lim, B., & Rigoutsos, I. (2008). MicroRNAs to Nanog, Oct4 and Sox2 coding regions modulate embryonic stem cell differentiation. Nature, 455(7216), 1124–1128. https://doi.org/10.1038/nature07299CrossRefPubMed

27.

Vasudevan, S., Tong, Y., & Steitz, J. A. (2007). Switching from repression to activation: microRNAs can up-regulate translation. Science, 318(5858), 1931–1934. https://doi.org/10.1126/science.1149460CrossRefPubMed

28.

Ørom, U. A., Nielsen, F. C., & Lund, A. H. (2008). MicroRNA-10a binds the 5'UTR of ribosomal protein mRNAs and enhances their translation. Molecular Cell, 30(4), 460–471. https://doi.org/10.1016/j.molcel.2008.05.001CrossRefPubMed

29.

Henke, J. I., Goergen, D., Zheng, J., Song, Y., Schüttler, C. G., Fehr, C., et al. (2008). microRNA-122 stimulates translation of hepatitis C virus RNA. The EMBO Journal, 27(24), 3300–3310. https://doi.org/10.1038/emboj.2008.244CrossRefPubMedPubMedCentral

30.

Filipowicz, W., Bhattacharyya, S. N., & Sonenberg, N. (2008). Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nature Reviews Genetics, 9(2), 102–114.CrossRefPubMed

31.

Huang, S., Tan, X., Huang, Z., Chen, Z., Lin, P., & Fu, S. W. (2018). microRNA biomarkers in colorectal cancer liver metastasis. Journal of Cancer, 9(21), 3867–3873. https://doi.org/10.7150/jca.28588CrossRefPubMedPubMedCentral

32.

Zhang, L.-F., Jiang, S., & Liu, M.-F. (2017). MicroRNA regulation and analytical methods in cancer cell metabolism. Cellular and Molecular Life Sciences, 74(16), 2929–2941. https://doi.org/10.1007/s00018-017-2508-yCrossRefPubMed

33.

Syed, S. N., Frank, A. C., Raue, R., & Brüne, B. (2019). MicroRNA-A Tumor Trojan Horse for Tumor-Associated Macrophages. Cells, 8(12). https://doi.org/10.3390/cells8121482

34.

Mirzaei, S., Zarrabi, A., Hashemi, F., Zabolian, A., Saleki, H., Ranjbar, A., et al. (2021). Regulation of Nuclear Factor-KappaB (NF-κB) signaling pathway by non-coding RNAs in cancer: Inhibiting or promoting carcinogenesis? Cancer Letters, 509, 63–80. https://doi.org/10.1016/j.canlet.2021.03.025CrossRefPubMed

35.

Ashrafizadeh, M., Hushmandi, K., Hashemi, M., Akbari, M. E., Kubatka, P., Raei, M., et al. (2020). Role of microRNA/Epithelial-to-Mesenchymal Transition Axis in the Metastasis of Bladder. Cancer., 10(8), 1159.

36.

Ashrafizadeh, M., Zarrabi, A., Hushmandi, K., Hashemi, F., Moghadam, E. R., Owrang, M., et al. (2021). Lung cancer cells and their sensitivity/resistance to cisplatin chemotherapy: Role of microRNAs and upstream mediators. Cellular Signalling, 78, 109871. https://doi.org/10.1016/j.cellsig.2020.109871CrossRefPubMed

37.

Dutta, M., Das, B., Mohapatra, D., Behera, P., Senapati, S., & Roychowdhury, A. (2022). MicroRNA-217 modulates pancreatic cancer progression via targeting ATAD2. Life Sciences, 301, 120592. https://doi.org/10.1016/j.lfs.2022.120592CrossRefPubMed

38.

Kong, P., Zhu, X., Geng, Q., Xia, L., Sun, X., Chen, Y., et al. (2017). The microRNA-423-3p-Bim Axis Promotes Cancer Progression and Activates Oncogenic Autophagy in Gastric Cancer. Molecular Therapy, 25(4), 1027–1037. https://doi.org/10.1016/j.ymthe.2017.01.013CrossRefPubMedPubMedCentral

39.

Quinn, J. J., & Chang, H. Y. (2016). Unique features of long non-coding RNA biogenesis and function. Nature Reviews Genetics, 17(1), 47–62. https://doi.org/10.1038/nrg.2015.10CrossRefPubMed

40.

Wooten, S., & Smith, K. N. (2022). Long non-coding RNA OIP5-AS1 (Cyrano): A context-specific regulator of normal and disease processes. Clinical and Translational Medicine, 12(1), e706. https://doi.org/10.1002/ctm2.706CrossRefPubMedPubMedCentral

41.

Yang, G., Lu, X., & Yuan, L. (2014). LncRNA: a link between RNA and cancer. Biochimica et Biophysica Acta, 1839(11), 1097–1109. https://doi.org/10.1016/j.bbagrm.2014.08.012CrossRefPubMed

42.

Hashemi, M., Hajimazdarany, S., Mohan, C. D., Mohammadi, M., Rezaei, S., Olyaee, Y., et al. (2022). Long non-coding RNA/epithelial-mesenchymal transition axis in human cancers: Tumorigenesis, chemoresistance, and radioresistance. Pharmacological Research, 186, 106535. https://doi.org/10.1016/j.phrs.2022.106535CrossRefPubMed

43.

Mohan, C. D., Rangappa, S., Nayak, S. C., Sethi, G., & Rangappa, K. S. (2021). Paradoxical functions of long noncoding RNAs in modulating STAT3 signaling pathway in hepatocellular carcinoma. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1876(1), 188574. https://doi.org/10.1016/j.bbcan.2021.188574CrossRefPubMed

44.

Wen, A., Luo, L., Du, C., & Luo, X. (2021). Long non-coding RNA miR155HG silencing restrains ovarian cancer progression by targeting the microRNA-155-5p/tyrosinase-related protein 1 axis. Experimental and Therapeutic Medicine, 22(5), 1237. https://doi.org/10.3892/etm.2021.10672CrossRefPubMedPubMedCentral

45.

Mo, C., Wu, J., Sui, J., Deng, Y., Li, M., Cao, Z., et al. (2022). Long non-coding RNA LINC01793 as a potential diagnostic biomarker of hepatitis B virus-related hepatocellular carcinoma. Clinical Biochemistry. https://doi.org/10.1016/j.clinbiochem.2022.06.006

46.

Liang, M., Zhu, B., Wang, M., & Jin, J. (2022). Knockdown of long non-coding RNA DDX11-AS1 inhibits the proliferation, migration and paclitaxel resistance of breast cancer cells by upregulating microRNA-497 expression. Molecular Medicine Reports, 25(4). https://doi.org/10.3892/mmr.2022.12639

47.

Wang, W., Zhang, Z., Li, Y., Gu, A., Wang, Y., Cai, Y., et al. (2022). Down-regulated long non-coding RNA LHFPL3 antisense RNA 1 inhibits the radiotherapy resistance of nasopharyngeal carcinoma via modulating microRNA-143-5p/homeobox A6 axis. Bioengineered, 13(3), 5421–5433. https://doi.org/10.1080/21655979.2021.2024386CrossRefPubMedPubMedCentral

48.

Rong, D., Sun, H., Li, Z., Liu, S., Dong, C., Fu, K., et al. (2017). An emerging function of circRNA-miRNAs-mRNA axis in human diseases. Oncotarget, 8(42), 73271–73281. https://doi.org/10.18632/oncotarget.19154CrossRefPubMedPubMedCentral

49.

Nigro, J. M., Cho, K. R., Fearon, E. R., Kern, S. E., Ruppert, J. M., Oliner, J. D., et al. (1991). Scrambled exons. Cell, 64(3), 607–613. https://doi.org/10.1016/0092-8674(91)90244-sCrossRefPubMed

50.

Sanger, H. L., Klotz, G., Riesner, D., Gross, H. J., & Kleinschmidt, A. K. (1976). Viroids are single-stranded covalently closed circular RNA molecules existing as highly base-paired rod-like structures. Proceedings of the National Academy of Sciences of the United States of America, 73(11), 3852–3856. https://doi.org/10.1073/pnas.73.11.3852CrossRefPubMedPubMedCentral

51.

Kolakofsky, D. (1976). Isolation and characterization of Sendai virus DI-RNAs. Cell, 8(4), 547–555. https://doi.org/10.1016/0092-8674(76)90223-3CrossRefPubMed

52.

Zhou, G. R., Huang, D. P., Sun, Z. F., & Zhang, X. F. (2020). Characteristics and prognostic significance of circRNA-100876 in patients with colorectal cancer. European Review for Medical and Pharmacological Sciences, 24(22), 11587–11593. https://doi.org/10.26355/eurrev_202011_23801CrossRefPubMed

53.

Ishola, A. A., Chien, C. S., Yang, Y. P., Chien, Y., Yarmishyn, A. A., Tsai, P. H., et al. (2022). Oncogenic circRNA C190 Promotes Non-Small Cell Lung Cancer via Modulation of the EGFR/ERK Pathway. Cancer Research, 82(1), 75–89. https://doi.org/10.1158/0008-5472.Can-21-1473CrossRefPubMed

54.

Cai, A., Hu, Y., Zhou, Z., Qi, Q., Wu, Y., Dong, P., et al. (2022). PIWI-Interacting RNAs (piRNAs): Promising Applications as Emerging Biomarkers for Digestive System Cancer. Frontiers in Molecular Biosciences, 9. https://doi.org/10.3389/fmolb.2022.848105

55.

Xiao, Y., & Ke, A. (2016). PIWI Takes a Giant Step. Cell, 167(2), 310–312. https://doi.org/10.1016/j.cell.2016.09.043CrossRefPubMed

56.

Ozata, D. M., Gainetdinov, I., Zoch, A., O’Carroll, D., & Zamore, P. D. (2019). PIWI-interacting RNAs: small RNAs with big functions. Nature Reviews Genetics, 20(2), 89–108. https://doi.org/10.1038/s41576-018-0073-3CrossRefPubMed

57.

Tan, L., Mai, D., Zhang, B., Jiang, X., Zhang, J., Bai, R., et al. (2019). PIWI-interacting RNA-36712 restrains breast cancer progression and chemoresistance by interaction with SEPW1 pseudogene SEPW1P RNA. Molecular Cancer, 18(1), 9. https://doi.org/10.1186/s12943-019-0940-3CrossRefPubMedPubMedCentral

58.

Cheng, J., Guo, J. M., Xiao, B. X., Miao, Y., Jiang, Z., Zhou, H., et al. (2011). piRNA, the new non-coding RNA, is aberrantly expressed in human cancer cells. Clinica Chimica Acta, 412(17-18), 1621–1625. https://doi.org/10.1016/j.cca.2011.05.015CrossRef

59.

Di Fazio, A., & Gullerova, M. (2023). An old friend with a new face: tRNA-derived small RNAs with big regulatory potential in cancer biology. British Journal of Cancer, 128(9), 1625–1635. https://doi.org/10.1038/s41416-023-02191-4CrossRefPubMedPubMedCentral

60.

Wen, J.-T., Huang, Z.-H., Li, Q.-H., Chen, X., Qin, H.-L., & Zhao, Y. (2021). Research progress on the tsRNA classification, function, and application in gynecological malignant tumors. Cell Death Discovery, 7(1), 388. https://doi.org/10.1038/s41420-021-00789-2CrossRefPubMedPubMedCentral

61.

Li, X., Liu, X., Zhao, D., Cui, W., Wu, Y., Zhang, C., et al. (2021). tRNA-derived small RNAs: novel regulators of cancer hallmarks and targets of clinical application. Cell Death Discovery, 7(1), 249. https://doi.org/10.1038/s41420-021-00647-1CrossRefPubMedPubMedCentral

62.

Ivanov, P., Emara, M. M., Villen, J., Gygi, S. P., & Anderson, P. (2011). Angiogenin-induced tRNA fragments inhibit translation initiation. Molecular Cell, 43(4), 613–623. https://doi.org/10.1016/j.molcel.2011.06.022CrossRefPubMedPubMedCentral

63.

Haussecker, D., Huang, Y., Lau, A., Parameswaran, P., Fire, A. Z., & Kay, M. A. (2010). Human tRNA-derived small RNAs in the global regulation of RNA silencing. Rna, 16(4), 673–695. https://doi.org/10.1261/rna.2000810CrossRefPubMedPubMedCentral

64.

Goodarzi, H., Liu, X., Nguyen, H. C., Zhang, S., Fish, L., & Tavazoie, S. F. (2015). Endogenous tRNA-Derived Fragments Suppress Breast Cancer Progression via YBX1 Displacement. Cell, 161(4), 790–802. https://doi.org/10.1016/j.cell.2015.02.053CrossRefPubMedPubMedCentral

65.

Saikia, M., Jobava, R., Parisien, M., Putnam, A., Krokowski, D., Gao, X. H., et al. (2014). Angiogenin-cleaved tRNA halves interact with cytochrome c, protecting cells from apoptosis during osmotic stress. Molecular and Cellular Biology, 34(13), 2450–2463. https://doi.org/10.1128/mcb.00136-14CrossRefPubMedPubMedCentral

66.

Shao, Y., Sun, Q., Liu, X., Wang, P., Wu, R., & Ma, Z. (2017). tRF-Leu-CAG promotes cell proliferation and cell cycle in non-small cell lung cancer. Chemical Biology & Drug Design, 90(5), 730–738. https://doi.org/10.1111/cbdd.12994CrossRef

67.

Luan, N., Chen, Y., Li, Q., Mu, Y., Zhou, Q., Ye, X., et al. (2021). TRF-20-M0NK5Y93 suppresses the metastasis of colon cancer cells by impairing the epithelial-to-mesenchymal transition through targeting Claudin-1. American Journal of Translational Research, 13(1), 124–142.PubMedPubMedCentral

68.

He, C., Wang, L., Zhang, J., & Xu, H. (2017). Hypoxia-inducible microRNA-224 promotes the cell growth, migration and invasion by directly targeting RASSF8 in gastric cancer. Molecular Cancer, 16(1), 35. https://doi.org/10.1186/s12943-017-0603-1CrossRefPubMedPubMedCentral

69.

Zhu, G., Zhou, L., Liu, H., Shan, Y., & Zhang, X. (2018). MicroRNA-224 Promotes Pancreatic Cancer Cell Proliferation and Migration by Targeting the TXNIP-Mediated HIF1α Pathway. Cellular Physiology and Biochemistry, 48(4), 1735–1746. https://doi.org/10.1159/000492309CrossRefPubMed

70.

Xia, M., Wei, J., & Tong, K. (2016). MiR-224 promotes proliferation and migration of gastric cancer cells through targeting PAK4. Pharmazie, 71(8), 460–464. https://doi.org/10.1691/ph.2016.6580CrossRefPubMed

71.

Zhang, Y., Li, C. F., Ma, L. J., Ding, M., & Zhang, B. (2016). MicroRNA-224 aggrevates tumor growth and progression by targeting mTOR in gastric cancer. International Journal of Oncology, 49(3), 1068–1080. https://doi.org/10.3892/ijo.2016.3581CrossRefPubMed

72.

Li, Y., Zhao, L., Qi, Y., & Yang, X. (2019). MicroRNA-214 upregulates HIF-1α and VEGF by targeting ING4 in lung cancer cells. Molecular Medicine Reports, 19(6), 4935–4945. https://doi.org/10.3892/mmr.2019.10170CrossRefPubMed

73.

Ji, Z., Wang, X., Liu, Y., Zhong, M., Sun, J., & Shang, J. (2022). MicroRNA-574-3p Regulates HIF-α Isoforms Promoting Gastric Cancer Epithelial-Mesenchymal Transition via Targeting CUL2. Digestive Diseases and Sciences, 67(8), 3714–3724. https://doi.org/10.1007/s10620-021-07263-0CrossRefPubMed

74.

Xia, X., Wang, S., Ni, B., Xing, S., Cao, H., Zhang, Z., et al. (2020). Hypoxic gastric cancer-derived exosomes promote progression and metastasis via MiR-301a-3p/PHD3/HIF-1α positive feedback loop. Oncogene, 39(39), 6231–6244. https://doi.org/10.1038/s41388-020-01425-6CrossRefPubMed

75.

Kelly, T. J., Souza, A. L., Clish, C. B., & Puigserver, P. (2011). A hypoxia-induced positive feedback loop promotes hypoxia-inducible factor 1alpha stability through miR-210 suppression of glycerol-3-phosphate dehydrogenase 1-like. Molecular and Cellular Biology, 31(13), 2696–2706. https://doi.org/10.1128/mcb.01242-10CrossRefPubMedPubMedCentral

76.

Du, Y., Wei, N., Ma, R., Jiang, S., & Song, D. (2020). A miR-210-3p regulon that controls the Warburg effect by modulating HIF-1α and p53 activity in triple-negative breast cancer. Cell Death & Disease, 11(9), 731. https://doi.org/10.1038/s41419-020-02952-6CrossRef

77.

DeBerardinis, R. J., Lum, J. J., Hatzivassiliou, G., Thompson, C. B. J. C., & m. (2008). The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metabolism, 7(1), 11–20.CrossRefPubMed

78.

Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell, 144(5), 646–674.CrossRefPubMed

79.

Hsu, P. P., & Sabatini, D. M. J. C. (2008). Cancer cell metabolism: Warburg and beyond., 134(5), 703–707.

80.

Vander Heiden, M. G., Cantley, L. C., Thompson, C. B. J., & s. (2009). Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science, 324(5930), 1029–1033.CrossRefPubMedPubMedCentral

81.

DeBerardinis, R. J., & Chandel, N. S. (2016). Fundamentals of cancer metabolism. Science Advances, 2(5), e1600200. https://doi.org/10.1126/sciadv.1600200CrossRefPubMedPubMedCentral

82.

Lee, N., & Kim, D. (2016). Cancer metabolism: fueling more than just growth. Molecules and Cells, 39(12), 847.CrossRefPubMedPubMedCentral

83.

Pavlova, N. N., Thompson, C. B. J. C., & m. (2016). The emerging hallmarks of cancer metabolism. Cell Metabolism, 23(1), 27–47.CrossRefPubMedPubMedCentral

84.

Zhang, S., Zhang, R., Xu, R., Shang, J., He, H., & Yang, Q. (2020). MicroRNA-574-5p in gastric cancer cells promotes angiogenesis by targeting protein tyrosine phosphatase non-receptor type 3 (PTPN3). Gene, 733, 144383. https://doi.org/10.1016/j.gene.2020.144383CrossRefPubMed

85.

Seok, J. K., Lee, S. H., Kim, M. J., & Lee, Y. M. (2014). MicroRNA-382 induced by HIF-1α is an angiogenic miR targeting the tumor suppressor phosphatase and tensin homolog. Nucleic Acids Research, 42(12), 8062–8072. https://doi.org/10.1093/nar/gku515CrossRefPubMedPubMedCentral

86.

Qiu, H., Chen, F., & Chen, M. (2019). MicroRNA-138 negatively regulates the hypoxia-inducible factor 1α to suppress melanoma growth and metastasis. Biol Open, 8(8). https://doi.org/10.1242/bio.042937

87.

Wu, F., Huang, W., & Wang, X. (2015). microRNA-18a regulates gastric carcinoma cell apoptosis and invasion by suppressing hypoxia-inducible factor-1α expression. Experimental and Therapeutic Medicine, 10(2), 717–722. https://doi.org/10.3892/etm.2015.2546CrossRefPubMedPubMedCentral

88.

Shi, J., Wang, H., Feng, W., Huang, S., An, J., Qiu, Y., et al. (2020). MicroRNA-130a targeting hypoxia-inducible factor 1 alpha suppresses cell metastasis and Warburg effect of NSCLC cells under hypoxia. Life Sciences, 255, 117826. https://doi.org/10.1016/j.lfs.2020.117826CrossRefPubMed

89.

Choi, J. Y., Seok, H. J., Kim, R. K., Choi, M. Y., Lee, S. J., & Bae, I. H. (2021). miR-519d-3p suppresses tumorigenicity and metastasis by inhibiting Bcl-w and HIF-1α in NSCLC. Mol Ther Oncolytics, 22, 368–379. https://doi.org/10.1016/j.omto.2021.06.015CrossRefPubMedPubMedCentral

90.

Hu, Q., Liu, F., Yan, T., Wu, M., Ye, M., Shi, G., et al. (2019). MicroRNA-576-3p inhibits the migration and proangiogenic abilities of hypoxia-treated glioma cells through hypoxia-inducible factor-1α. International Journal of Molecular Medicine, 43(6), 2387–2397. https://doi.org/10.3892/ijmm.2019.4157CrossRefPubMedPubMedCentral

91.

Cheng, C. W., Chen, P. M., Hsieh, Y. H., Weng, C. C., Chang, C. W., Yao, C. C., et al. (2015). Foxo3a-mediated overexpression of microRNA-622 suppresses tumor metastasis by repressing hypoxia-inducible factor-1α in ERK-responsive lung cancer. Oncotarget, 6(42), 44222–44238. https://doi.org/10.18632/oncotarget.5826CrossRefPubMedPubMedCentral

92.

Ang, H. L., Mohan, C. D., Shanmugam, M. K., Leong, H. C., Makvandi, P., Rangappa, K. S., et al. (2023). Mechanism of epithelial-mesenchymal transition in cancer and its regulation by natural compounds. Medicinal Research Reviews, 43(4), 1141–1200. https://doi.org/10.1002/med.21948CrossRefPubMed

93.

Huang, X., Liu, F., Jiang, Z., Guan, H., & Jia, Q. (2020). CREB1 Suppresses Transcription of microRNA-186 to Promote Growth, Invasion and Epithelial-Mesenchymal Transition of Gastric Cancer Cells Through the KRT8/HIF-1α Axis. Cancer Management and Research, 12, 9097–9111. https://doi.org/10.2147/cmar.S265187CrossRefPubMedPubMedCentral

94.

Peng, D., Wu, T., Wang, J., Huang, J., Zheng, L., Wang, P., et al. (2022). microRNA-671-5p reduces tumorigenicity of ovarian cancer via suppressing HDAC5 and HIF-1α expression. Chemico-Biological Interactions, 355, 109780. https://doi.org/10.1016/j.cbi.2021.109780CrossRefPubMed

95.

Hu, S., Cao, P., Kong, K., Han, P., Deng, Y., Li, F., et al. (2021). MicroRNA-449a delays lung cancer development through inhibiting KDM3A/HIF-1α axis. Journal of Translational Medicine, 19(1), 224. https://doi.org/10.1186/s12967-021-02881-8CrossRefPubMedPubMedCentral

96.

Li, X., Li, H., Zhang, R., Liu, J., & Liu, J. (2015). MicroRNA-449a inhibits proliferation and induces apoptosis by directly repressing E2F3 in gastric cancer. Cellular Physiology and Biochemistry, 35(5), 2033–2042. https://doi.org/10.1159/000374010CrossRefPubMed

97.

Xu, B., Zhang, X., Wang, S., & Shi, B. (2018). MiR-449a suppresses cell migration and invasion by targeting PLAGL2 in breast cancer. Pathology, Research and Practice, 214(5), 790–795. https://doi.org/10.1016/j.prp.2017.12.012CrossRefPubMed

98.

Wang, L., Zhao, Y., Xiong, W., Ye, W., Zhao, W., & Hua, Y. (2019). MicroRNA-449a Is Downregulated in Cervical Cancer and Inhibits Proliferation, Migration, and Invasion. Oncol Res Treat, 42(11), 564–571. https://doi.org/10.1159/000502122CrossRefPubMed

99.

Wu, X., Han, Y., Liu, F., & Ruan, L. (2020). Downregulations of miR-449a and miR-145-5p Act as Prognostic Biomarkers for Endometrial Cancer. Journal of Computational Biology, 27(5), 834–844. https://doi.org/10.1089/cmb.2019.0215CrossRefPubMed

100.

Yogev, O., Henderson, S., Hayes, M. J., Marelli, S. S., Ofir-Birin, Y., Regev-Rudzki, N., et al. (2017). Herpesviruses shape tumour microenvironment through exosomal transfer of viral microRNAs. PLoS Pathogens, 13(8), e1006524. https://doi.org/10.1371/journal.ppat.1006524CrossRefPubMedPubMedCentral

101.

Pucci, F., & Pittet, M. J. (2013). Molecular pathways: tumor-derived microvesicles and their interactions with immune cells in vivo. Clinical Cancer Research, 19(10), 2598–2604. https://doi.org/10.1158/1078-0432.Ccr-12-0962CrossRefPubMedPubMedCentral

102.

King, H. W., Michael, M. Z., & Gleadle, J. M. (2012). Hypoxic enhancement of exosome release by breast cancer cells. BMC Cancer, 12, 421. https://doi.org/10.1186/1471-2407-12-421CrossRefPubMedPubMedCentral

103.

Kucharzewska, P., Christianson, H. C., Welch, J. E., Svensson, K. J., Fredlund, E., Ringnér, M., et al. (2013). Exosomes reflect the hypoxic status of glioma cells and mediate hypoxia-dependent activation of vascular cells during tumor development. Proceedings of the National Academy of Sciences of the United States of America, 110(18), 7312–7317. https://doi.org/10.1073/pnas.1220998110CrossRefPubMedPubMedCentral

104.

Li, S., Yi, M., Dong, B., Jiao, Y., Luo, S., & Wu, K. (2020). The roles of exosomes in cancer drug resistance and its therapeutic application. Clinical and Translational Medicine, 10(8), e257. https://doi.org/10.1002/ctm2.257CrossRefPubMedPubMedCentral

105.

Zhu, X., Shen, H., Yin, X., Yang, M., Wei, H., Chen, Q., et al. (2019). Macrophages derived exosomes deliver miR-223 to epithelial ovarian cancer cells to elicit a chemoresistant phenotype. Journal of Experimental & Clinical Cancer Research, 38(1), 81. https://doi.org/10.1186/s13046-019-1095-1CrossRef

106.

Xu, K., Zhan, Y., Yuan, Z., Qiu, Y., Wang, H., Fan, G., et al. (2019). Hypoxia Induces Drug Resistance in Colorectal Cancer through the HIF-1α/miR-338-5p/IL-6 Feedback Loop. Molecular Therapy, 27(10), 1810–1824. https://doi.org/10.1016/j.ymthe.2019.05.017CrossRefPubMedPubMedCentral

107.

Mohan, C. D., Rangappa, S., Preetham, H. D., Chandra Nayaka, S., Gupta, V. K., Basappa, S., et al. (2022). Targeting STAT3 signaling pathway in cancer by agents derived from Mother Nature. Seminars in Cancer Biology, 80, 157–182. https://doi.org/10.1016/j.semcancer.2020.03.016CrossRefPubMed

108.

Keerthy, H. K., Garg, M., Mohan, C. D., Madan, V., Kanojia, D., Shobith, R., et al. (2014). Synthesis and Characterization of Novel 2-Amino-Chromene-Nitriles that Target Bcl-2 in Acute Myeloid Leukemia Cell Lines. PLoS One, 9(9), e107118. https://doi.org/10.1371/journal.pone.0107118CrossRefPubMedPubMedCentral

109.

Anusha, S., Mohan, C. D., Ananda, H., Baburajeev, C. P., Rangappa, S., Mathai, J., et al. (2016). Adamantyl-tethered-biphenylic compounds induce apoptosis in cancer cells by targeting Bcl homologs. Bioorganic & Medicinal Chemistry Letters, 26(3), 1056–1060. https://doi.org/10.1016/j.bmcl.2015.12.026CrossRef

110.

Mohan, C. D., Kim, C., Siveen, K. S., Manu, K. A., Rangappa, S., Chinnathambi, A., et al. (2021). Crocetin imparts antiproliferative activity via inhibiting STAT3 signaling in hepatocellular carcinoma. IUBMB Life, 73(11), 1348–1362. https://doi.org/10.1002/iub.2555CrossRefPubMed

111.

Liu, H., Chen, C., Zeng, J., Zhao, Z., & Hu, Q. (2021). MicroRNA-210-3p is transcriptionally upregulated by hypoxia induction and thus promoting EMT and chemoresistance in glioma cells. PLoS One, 16(7), e0253522. https://doi.org/10.1371/journal.pone.0253522CrossRefPubMedPubMedCentral

112.

Ge, X., Liu, X., Lin, F., Li, P., Liu, K., Geng, R., et al. (2016). MicroRNA-421 regulated by HIF-1α promotes metastasis, inhibits apoptosis, and induces cisplatin resistance by targeting E-cadherin and caspase-3 in gastric cancer. Oncotarget, 7(17), 24466–24482. https://doi.org/10.18632/oncotarget.8228CrossRefPubMedPubMedCentral

113.

Koo, T., Cho, B. J., Kim, D. H., Park, J. M., Choi, E. J., Kim, H. H., et al. (2017). MicroRNA-200c increases radiosensitivity of human cancer cells with activated EGFR-associated signaling. Oncotarget, 8(39), 65457–65468. https://doi.org/10.18632/oncotarget.18924CrossRefPubMedPubMedCentral

114.

Byun, Y., Choi, Y. C., Jeong, Y., Lee, G., Yoon, S., Jeong, Y., et al. (2019). MiR-200c downregulates HIF-1α and inhibits migration of lung cancer cells. Cellular & Molecular Biology Letters, 24, 28. https://doi.org/10.1186/s11658-019-0152-2CrossRef

115.

Xu, Z., Zhu, C., Chen, C., Zong, Y., Feng, H., Liu, D., et al. (2018). CCL19 suppresses angiogenesis through promoting miR-206 and inhibiting Met/ERK/Elk-1/HIF-1α/VEGF-A pathway in colorectal cancer. Cell Death & Disease, 9(10), 974. https://doi.org/10.1038/s41419-018-1010-2CrossRef

116.

Xu, F., Hu, Y., Gao, J., Wang, J., Xie, Y., Sun, F., et al. (2022). HIF-1α/Malat1/miR-141 Axis Activates Autophagy to Increase Proliferation, Migration, and Invasion in Triple-negative Breast Cancer. Current Cancer Drug Targets. https://doi.org/10.2174/1568009623666221228104833

117.

Zhang, Y., Yan, J., Wang, L., Dai, H., Li, N., Hu, W., et al. (2017). HIF-1α Promotes Breast Cancer Cell MCF-7 Proliferation and Invasion Through Regulating miR-210. Cancer Biotherapy & Radiopharmaceuticals, 32(8), 297–301. https://doi.org/10.1089/cbr.2017.2270CrossRef

118.

He, M., Zhan, M., Chen, W., Xu, S., Long, M., Shen, H., et al. (2017). MiR-143-5p Deficiency Triggers EMT and Metastasis by Targeting HIF-1α in Gallbladder Cancer. Cellular Physiology and Biochemistry, 42(5), 2078–2092. https://doi.org/10.1159/000479903CrossRefPubMed

119.

Zhang, C., Tian, W., Meng, L., Qu, L., & Shou, C. (2016). PRL-3 promotes gastric cancer migration and invasion through a NF-κB-HIF-1α-miR-210 axis. Journal of Molecular Medicine (Berlin, Germany), 94(4), 401–415. https://doi.org/10.1007/s00109-015-1350-7CrossRefPubMed

120.

Lv, D., Shen, T., Yao, J., Yang, Q., Xiang, Y., & Ma, Z. (2021). HIF-1α Induces HECTD2 Up-Regulation and Aggravates the Malignant Progression of Renal Cell Cancer via Repressing miR-320a. Frontiers in Cell and Development Biology, 9, 775642. https://doi.org/10.3389/fcell.2021.775642CrossRef

121.

Zhou, B., Lei, J. H., Wang, Q., Qu, T. F., Cha, L. C., Zhan, H. X., et al. (2022). Cancer-associated fibroblast-secreted miR-421 promotes pancreatic cancer by regulating the SIRT3/H3K9Ac/HIF-1α axis. The Kaohsiung Journal of Medical Sciences, 38(11), 1080–1092. https://doi.org/10.1002/kjm2.12590CrossRefPubMed

122.

Lu, Y., Ji, N., Wei, W., Sun, W., Gong, X., & Wang, X. (2017). MiR-142 modulates human pancreatic cancer proliferation and invasion by targeting hypoxia-inducible factor 1 (HIF-1α) in the tumor microenvironments. Biol Open, 6(2), 252–259. https://doi.org/10.1242/bio.021774CrossRefPubMedPubMedCentral

123.

Chiang, C. H., Chu, P. Y., Hou, M. F., & Hung, W. C. (2016). MiR-182 promotes proliferation and invasion and elevates the HIF-1α-VEGF-A axis in breast cancer cells by targeting FBXW7. American Journal of Cancer Research, 6(8), 1785–1798.PubMedPubMedCentral

124.

Jin, F., Yang, R., Wei, Y., Wang, D., Zhu, Y., Wang, X., et al. (2019). HIF-1α-induced miR-23a∼27a∼24 cluster promotes colorectal cancer progression via reprogramming metabolism. Cancer Letters, 440-441, 211–222. https://doi.org/10.1016/j.canlet.2018.10.025CrossRefPubMed

125.

Ma, C. N., Wo, L. L., Wang, D. F., Zhou, C. X., Li, J. C., Zhang, X., et al. (2021). Hypoxia activated long non-coding RNA HABON regulates the growth and proliferation of hepatocarcinoma cells by binding to and antagonizing HIF-1 alpha. RNA Biology, 18(11), 1791–1806. https://doi.org/10.1080/15476286.2020.1871215CrossRefPubMedPubMedCentral

126.

Chen, F., Chen, J., Yang, L., Liu, J., Zhang, X., Zhang, Y., et al. (2019). Extracellular vesicle-packaged HIF-1α-stabilizing lncRNA from tumour-associated macrophages regulates aerobic glycolysis of breast cancer cells. Nature Cell Biology, 21(4), 498–510. https://doi.org/10.1038/s41556-019-0299-0CrossRefPubMed

127.

Hua, Q., Mi, B., Xu, F., Wen, J., Zhao, L., Liu, J., et al. (2020). Hypoxia-induced lncRNA-AC020978 promotes proliferation and glycolytic metabolism of non-small cell lung cancer by regulating PKM2/HIF-1α axis. Theranostics, 10(11), 4762–4778. https://doi.org/10.7150/thno.43839CrossRefPubMedPubMedCentral

128.

Xu, L., Huan, L., Guo, T., Wu, Y., Liu, Y., Wang, Q., et al. (2020). LncRNA SNHG11 facilitates tumor metastasis by interacting with and stabilizing HIF-1α. Oncogene, 39(46), 7005–7018. https://doi.org/10.1038/s41388-020-01512-8CrossRefPubMedPubMedCentral

129.

Liu, P., Huang, H., Qi, X., Bian, C., Cheng, M., Liu, L., et al. (2021). Hypoxia-Induced LncRNA-MIR210HG Promotes Cancer Progression By Inhibiting HIF-1α Degradation in Ovarian Cancer. Frontiers in Oncology, 11, 701488. https://doi.org/10.3389/fonc.2021.701488CrossRefPubMedPubMedCentral

130.

Mineo, M., Ricklefs, F., Rooj, A. K., Lyons, S. M., Ivanov, P., Ansari, K. I., et al. (2016). The Long Non-coding RNA HIF1A-AS2 Facilitates the Maintenance of Mesenchymal Glioblastoma Stem-like Cells in Hypoxic Niches. Cell Reports, 15(11), 2500–2509. https://doi.org/10.1016/j.celrep.2016.05.018CrossRefPubMed

131.

Tong, J., Xu, X., Zhang, Z., Ma, C., Xiang, R., Liu, J., et al. (2020). Hypoxia-induced long non-coding RNA DARS-AS1 regulates RBM39 stability to promote myeloma malignancy. Haematologica, 105(6), 1630–1640. https://doi.org/10.3324/haematol.2019.218289CrossRefPubMedPubMedCentral

132.

Qian, Y., Wang, R., Wei, W., Wang, M., & Wang, S. (2021). Resveratrol reverses the cadmium-promoted migration, invasion, and epithelial-mesenchymal transition procession by regulating the expression of ZEB1. Human & Experimental Toxicology, 40(12_suppl), S331–s338. https://doi.org/10.1177/09603271211041678CrossRef

133.

Kalinkova, L., Nikolaieva, N., Smolkova, B., Ciernikova, S., Kajo, K., Bella, V., et al. (2021). miR-205-5p Downregulation and ZEB1 Upregulation Characterize the Disseminated Tumor Cells in Patients with Invasive Ductal Breast Cancer. International Journal of Molecular Sciences, 23(1). https://doi.org/10.3390/ijms23010103

134.

Deng, S. J., Chen, H. Y., Ye, Z., Deng, S. C., Zhu, S., Zeng, Z., et al. (2018). Hypoxia-induced LncRNA-BX111 promotes metastasis and progression of pancreatic cancer through regulating ZEB1 transcription. Oncogene, 37(44), 5811–5828. https://doi.org/10.1038/s41388-018-0382-1CrossRefPubMed

135.

Zhang, J., Jin, H. Y., Wu, Y., Zheng, Z. C., Guo, S., Wang, Y., et al. (2019). Hypoxia-induced LncRNA PCGEM1 promotes invasion and metastasis of gastric cancer through regulating SNAI1. Clinical and Translational Oncology, 21(9), 1142–1151. https://doi.org/10.1007/s12094-019-02035-9CrossRefPubMed

136.

Li, L., Wang, M., Mei, Z., Cao, W., Yang, Y., Wang, Y., et al. (2017). lncRNAs HIF1A-AS2 facilitates the up-regulation of HIF-1α by sponging to miR-153-3p, whereby promoting angiogenesis in HUVECs in hypoxia. Biomedicine & Pharmacotherapy, 96, 165–172. https://doi.org/10.1016/j.biopha.2017.09.113CrossRef

137.

Barth, D. A., Prinz, F., Teppan, J., Jonas, K., Klec, C., & Pichler, M. (2020). Long-noncoding RNA (lncRNA) in the regulation of hypoxia-inducible factor (HIF) in cancer. Non-coding RNA, 6(3), 27.CrossRefPubMedPubMedCentral

138.

Kanamori, A., Matsubara, D., Saitoh, Y., Fukui, Y., Gotoh, N., Kaneko, S., et al. (2020). Mint3 depletion restricts tumor malignancy of pancreatic cancer cells by decreasing SKP2 expression via HIF-1. Oncogene, 39(39), 6218–6230. https://doi.org/10.1038/s41388-020-01423-8CrossRefPubMedPubMedCentral

139.

Liu, M., Zhong, J., Zeng, Z., Huang, K., Ye, Z., Deng, S., et al. (2019). Hypoxia-induced feedback of HIF-1α and lncRNA-CF129 contributes to pancreatic cancer progression through stabilization of p53 protein. Theranostics, 9(16), 4795–4810. https://doi.org/10.7150/thno.30988CrossRefPubMedPubMedCentral

140.

Wang, X., Li, L., Zhao, K., Lin, Q., Li, H., Xue, X., et al. (2020). A novel LncRNA HITT forms a regulatory loop with HIF-1α to modulate angiogenesis and tumor growth. Cell Death and Differentiation, 27(4), 1431–1446. https://doi.org/10.1038/s41418-019-0449-8CrossRefPubMed

141.

Kim, K. H., & Roberts, C. W. (2016). Targeting EZH2 in cancer. Nature Medicine, 22(2), 128–134. https://doi.org/10.1038/nm.4036CrossRefPubMedPubMedCentral

142.

Sun, Y. W., Chen, Y. F., Li, J., Huo, Y. M., Liu, D. J., Hua, R., et al. (2014). A novel long non-coding RNA ENST00000480739 suppresses tumour cell invasion by regulating OS-9 and HIF-1α in pancreatic ductal adenocarcinoma. British Journal of Cancer, 111(11), 2131–2141. https://doi.org/10.1038/bjc.2014.520CrossRefPubMedPubMedCentral

143.

Zhang, W., Yuan, W., Song, J., Wang, S., & Gu, X. (2018). LncRNA CPS1-IT1 suppresses EMT and metastasis of colorectal cancer by inhibiting hypoxia-induced autophagy through inactivation of HIF-1α. Biochimie, 144, 21–27. https://doi.org/10.1016/j.biochi.2017.10.002CrossRefPubMed

144.

Wang, G., Dong, Y., Liu, H., Ji, N., Cao, J., Liu, A., et al. (2022). Long noncoding RNA (lncRNA) metallothionein 1 J, pseudogene (MT1JP) is downregulated in triple-negative breast cancer and upregulates microRNA-138 (miR-138) to downregulate hypoxia-inducible factor-1α (HIF-1α). Bioengineered, 13(5), 13718–13727. https://doi.org/10.1080/21655979.2022.2077906CrossRefPubMedPubMedCentral

145.

Li, W., Han, S., Hu, P., Chen, D., Zeng, Z., Hu, Y., et al. (2021). LncRNA ZNFTR functions as an inhibitor in pancreatic cancer by modulating ATF3/ZNF24/VEGFA pathway. Cell Death & Disease, 12(9), 830. https://doi.org/10.1038/s41419-021-04119-3CrossRef

146.

Zhu, Y., Wu, F., Gui, W., Zhang, N., Matro, E., Zhu, L., et al. (2021). A positive feedback regulatory loop involving the lncRNA PVT1 and HIF-1α in pancreatic cancer. Journal of Molecular Cell Biology, 13(9), 676–689. https://doi.org/10.1093/jmcb/mjab042CrossRefPubMedPubMedCentral

147.

Liu, Y.-F., Luo, D., Li, X., Li, Z.-Q., Yu, X., & Zhu, H.-W. (2021). PVT1 Knockdown Inhibits Autophagy and Improves Gemcitabine Sensitivity by Regulating the MiR-143/HIF-1α/VMP1 Axis in Pancreatic Cancer. Pancreas, 50(2), 227–234. https://doi.org/10.1097/mpa.0000000000001747CrossRefPubMed

148.

Zhang, L., Wu, H., Zhang, Y., Xiao, X., Chu, F., & Zhang, L. (2022). Induction of lncRNA NORAD accounts for hypoxia-induced chemoresistance and vasculogenic mimicry in colorectal cancer by sponging the miR-495-3p/ hypoxia-inducible factor-1α (HIF-1α). Bioengineered, 13(1), 950–962. https://doi.org/10.1080/21655979.2021.2015530CrossRefPubMed

149.

Jin, L., Ma, X., Zhang, N., Zhang, Q., Chen, X., Zhang, Z., et al. (2021). Targeting Oncogenic miR-181a-2-3p Inhibits Growth and Suppresses Cisplatin Resistance of Gastric Cancer. Cancer Management and Research, 13, 8599–8609. https://doi.org/10.2147/cmar.S332713CrossRefPubMedPubMedCentral

150.

Qiao, X. L., Zhong, Z. L., Dong, Y., & Gao, F. (2020). LncRNA HMGA1P4 promotes cisplatin-resistance in gastric cancer. European Review for Medical and Pharmacological Sciences, 24(17), 8830–8836. https://doi.org/10.26355/eurrev_202009_22822CrossRefPubMed

151.

Xu, Y. D., Shang, J., Li, M., & Zhang, Y. Y. (2019). LncRNA DANCR accelerates the development of multidrug resistance of gastric cancer. European Review for Medical and Pharmacological Sciences, 23(7), 2794–2802. https://doi.org/10.26355/eurrev_201904_17554CrossRefPubMed

152.

Zhang, X. W., Bu, P., Liu, L., Zhang, X. Z., & Li, J. (2015). Overexpression of long non-coding RNA PVT1 in gastric cancer cells promotes the development of multidrug resistance. Biochemical and Biophysical Research Communications, 462(3), 227–232. https://doi.org/10.1016/j.bbrc.2015.04.121CrossRefPubMed

153.

Yu, Z., Wang, Y., Deng, J., Liu, D., Zhang, L., Shao, H., et al. (2021). Long non-coding RNA COL4A2-AS1 facilitates cell proliferation and glycolysis of colorectal cancer cells via miR-20b-5p/hypoxia inducible factor 1 alpha subunit axis. Bioengineered, 12(1), 6251–6263. https://doi.org/10.1080/21655979.2021.1969833CrossRefPubMedPubMedCentral

154.

Zhang, H., Yao, B., Tang, S., & Chen, Y. (2019). LINK-A Long Non-Coding RNA (lncRNA) Participates in Metastasis of Ovarian Carcinoma and Upregulates Hypoxia-Inducible Factor 1 (HIF1α). Medical Science Monitor, 25, 2221–2227. https://doi.org/10.12659/msm.913609CrossRefPubMedPubMedCentral

155.

Liu, D., & Li, H. (2019). Long non-coding RNA GEHT1 promoted the proliferation of ovarian cancer cells via modulating the protein stability of HIF1α. Bioscience Reports, 39(5). https://doi.org/10.1042/bsr20181650

156.

Zhang, T., Wang, F., Liao, Y., Yuan, L., & Zhang, B. (2019). LncRNA AWPPH promotes the invasion and migration of glioma cells through the upregulation of HIF1α. Oncology Letters, 18(6), 6781–6786. https://doi.org/10.3892/ol.2019.11018CrossRefPubMedPubMedCentral

157.

Lin, Z., Song, J., Gao, Y., Huang, S., Dou, R., Zhong, P., et al. (2022). Hypoxia-induced HIF-1α/lncRNA-PMAN inhibits ferroptosis by promoting the cytoplasmic translocation of ELAVL1 in peritoneal dissemination from gastric cancer. Redox Biology, 52, 102312. https://doi.org/10.1016/j.redox.2022.102312CrossRefPubMedPubMedCentral

158.

Wang, Y., Chen, W., Lian, J., Zhang, H., Yu, B., Zhang, M., et al. (2020). The lncRNA PVT1 regulates nasopharyngeal carcinoma cell proliferation via activating the KAT2A acetyltransferase and stabilizing HIF-1α. Cell Death and Differentiation, 27(2), 695–710. https://doi.org/10.1038/s41418-019-0381-yCrossRefPubMed

159.

Jin, Y., Zhang, Z., Yu, Q., Zeng, Z., Song, H., Huang, X., et al. (2021). Positive Reciprocal Feedback of lncRNA ZEB1-AS1 and HIF-1α Contributes to Hypoxia-Promoted Tumorigenesis and Metastasis of Pancreatic Cancer. Frontiers in Oncology, 11, 761979. https://doi.org/10.3389/fonc.2021.761979CrossRefPubMedPubMedCentral

160.

Wu, F., Gao, H., Liu, K., Gao, B., Ren, H., Li, Z., et al. (2019). The lncRNA ZEB2-AS1 is upregulated in gastric cancer and affects cell proliferation and invasion via miR-143-5p/HIF-1α axis. Oncotargets and Therapy, 12, 657–667. https://doi.org/10.2147/ott.S175521CrossRefPubMedPubMedCentral

161.

Li, L., Ma, Y., Maerkeya, K., Reyanguly, D., & Han, L. (2021). LncRNA OIP5-AS1 Regulates the Warburg Effect Through miR-124-5p/IDH2/HIF-1α Pathway in Cervical Cancer. Frontiers in Cell and Development Biology, 9, 655018. https://doi.org/10.3389/fcell.2021.655018CrossRef

162.

Zhang, J., Du, C., Zhang, L., Wang, Y., Zhang, Y., & Li, J. (2022). LncRNA LINC00649 promotes the growth and metastasis of triple-negative breast cancer by maintaining the stability of HIF-1α through the NF90/NF45 complex. Cell Cycle, 21(10), 1034–1047. https://doi.org/10.1080/15384101.2022.2040283CrossRefPubMedPubMedCentral

163.

Yang, B., Jia, L., Ren, H., Jin, C., Ren, Q., Zhang, H., et al. (2020). LncRNA DLX6-AS1 increases the expression of HIF-1α and promotes the malignant phenotypes of nasopharyngeal carcinoma cells via targeting MiR-199a-5p. Molecular Genetics & Genomic Medicine, 8(1), e1017. https://doi.org/10.1002/mgg3.1017CrossRef

164.

Peng, X., Yan, J., & Cheng, F. (2020). LncRNA TMPO-AS1 up-regulates the expression of HIF-1α and promotes the malignant phenotypes of retinoblastoma cells via sponging miR-199a-5p. Pathology, Research and Practice, 216(4), 152853. https://doi.org/10.1016/j.prp.2020.152853CrossRefPubMed

165.

Zeng, Z., Xu, F. Y., Zheng, H., Cheng, P., Chen, Q. Y., Ye, Z., et al. (2019). LncRNA-MTA2TR functions as a promoter in pancreatic cancer via driving deacetylation-dependent accumulation of HIF-1α. Theranostics, 9(18), 5298–5314. https://doi.org/10.7150/thno.34559CrossRefPubMedPubMedCentral

166.

Sun, S., Xia, C., & Xu, Y. (2020). HIF-1α induced lncRNA LINC00511 accelerates the colorectal cancer proliferation through positive feedback loop. Biomedicine & Pharmacotherapy, 125, 110014. https://doi.org/10.1016/j.biopha.2020.110014CrossRef

167.

Dong, L., Cao, X., Luo, Y., Zhang, G., & Zhang, D. (2020). A Positive Feedback Loop of lncRNA DSCR8/miR-98-5p/STAT3/HIF-1α Plays a Role in the Progression of Ovarian Cancer. Frontiers in Oncology, 10, 1713. https://doi.org/10.3389/fonc.2020.01713CrossRefPubMedPubMedCentral

168.

Zhu, Y., Tong, Y., Wu, J., Liu, Y., & Zhao, M. (2019). Knockdown of LncRNA GHET1 suppresses prostate cancer cell proliferation by inhibiting HIF-1α/Notch-1 signaling pathway via KLF2. Biofactors, 45(3), 364–373. https://doi.org/10.1002/biof.1486CrossRefPubMed

169.

Li, X., Deng, S. J., Zhu, S., Jin, Y., Cui, S. P., Chen, J. Y., et al. (2016). Hypoxia-induced lncRNA-NUTF2P3-001 contributes to tumorigenesis of pancreatic cancer by derepressing the miR-3923/KRAS pathway. Oncotarget, 7(5), 6000–6014. https://doi.org/10.18632/oncotarget.6830CrossRefPubMedPubMedCentral

170.

Chen, Z., Hu, Z., Sui, Q., Huang, Y., Zhao, M., Li, M., et al. (2022). LncRNA FAM83A-AS1 facilitates tumor proliferation and the migration via the HIF-1α/ glycolysis axis in lung adenocarcinoma. International Journal of Biological Sciences, 18(2), 522–535. https://doi.org/10.7150/ijbs.67556CrossRefPubMedPubMedCentral

171.

Zhou, C., Huang, C., Wang, J., Huang, H., Li, J., Xie, Q., et al. (2017). LncRNA MEG3 downregulation mediated by DNMT3b contributes to nickel malignant transformation of human bronchial epithelial cells via modulating PHLPP1 transcription and HIF-1α translation. Oncogene, 36(27), 3878–3889. https://doi.org/10.1038/onc.2017.14CrossRefPubMedPubMedCentral

172.

Jiang, P., Hao, S., Xie, L., Xiang, G., Hu, W., Wu, Q., et al. (2021). LncRNA NEAT1 contributes to the acquisition of a tumor like-phenotype induced by PM 2.5 in lung bronchial epithelial cells via HIF-1α activation. Environmental Science and Pollution Research International, 28(32), 43382–43393. https://doi.org/10.1007/s11356-021-13735-7CrossRefPubMed

173.

Wang, C., Han, C., Zhang, Y., & Liu, F. (2018). LncRNA PVT1 regulate expression of HIF1α via functioning as ceRNA for miR-199a-5p in non-small cell lung cancer under hypoxia. Molecular Medicine Reports, 17(1), 1105–1110. https://doi.org/10.3892/mmr.2017.7962CrossRefPubMed

174.

Meng, F., Luo, X., Li, C., & Wang, G. (2022). LncRNA LINC00525 activates HIF-1α through miR-338-3p / UBE2Q1 / β-catenin axis to regulate the Warburg effect in colorectal cancer. Bioengineered, 13(2), 2554–2567. https://doi.org/10.1080/21655979.2021.2018538CrossRefPubMed

175.

Zhang, W., Wang, J., Chai, R., Zhong, G., Zhang, C., Cao, W., et al. (2018). Hypoxia-regulated lncRNA CRPAT4 promotes cell migration via regulating AVL9 in clear cell renal cell carcinomas. Oncotargets and Therapy, 11, 4537–4545. https://doi.org/10.2147/ott.S169155CrossRefPubMedPubMedCentral

176.

Piao, H. Y., Liu, Y., Kang, Y., Wang, Y., Meng, X. Y., Yang, D., et al. (2022). Hypoxia associated lncRNA HYPAL promotes proliferation of gastric cancer as ceRNA by sponging miR-431-5p to upregulate CDK14. Gastric Cancer, 25(1), 44–63. https://doi.org/10.1007/s10120-021-01213-5CrossRefPubMed

177.

Zhou, L., Jiang, J., Huang, Z., Jin, P., Peng, L., Luo, M., et al. (2022). Hypoxia-induced lncRNA STEAP3-AS1 activates Wnt/β-catenin signaling to promote colorectal cancer progression by preventing m(6)A-mediated degradation of STEAP3 mRNA. Molecular Cancer, 21(1), 168. https://doi.org/10.1186/s12943-022-01638-1CrossRefPubMedPubMedCentral

178.

Wang, L., Li, B., Bo, X., Yi, X., Xiao, X., & Zheng, Q. (2022). Hypoxia-induced LncRNA DACT3-AS1 upregulates PKM2 to promote metastasis in hepatocellular carcinoma through the HDAC2/FOXA3 pathway. Experimental & Molecular Medicine, 54(6), 848–860. https://doi.org/10.1038/s12276-022-00767-3CrossRef

179.

Jin, Y., Xie, H., Duan, L., Zhao, D., Ding, J., & Jiang, G. (2019). Long Non-Coding RNA CASC9 And HIF-1α Form A Positive Feedback Loop To Facilitate Cell Proliferation And Metastasis In Lung Cancer. Oncotargets and Therapy, 12, 9017–9027. https://doi.org/10.2147/ott.S226078CrossRefPubMedPubMedCentral

180.

Ma, H. N., Chen, H. J., Liu, J. Q., & Li, W. T. (2022). Long non-coding RNA DLEU1 promotes malignancy of breast cancer by acting as an indispensable coactivator for HIF-1α-induced transcription of CKAP2. Cell Death & Disease, 13(7), 625. https://doi.org/10.1038/s41419-022-04880-zCrossRef

181.

Liu, H., Wan, J., Feng, Q., Li, J., Liu, J., & Cui, S. (2022). Long non-coding RNA SOS1-IT1 promotes endometrial cancer progression by regulating hypoxia signaling pathway. J Cell Commun Signal, 16(2), 253–270. https://doi.org/10.1007/s12079-021-00651-1CrossRefPubMed

182.

Zhang, Y., Ma, H., & Chen, C. (2021). Long non-coding RNA PCED1B-AS1 promotes pancreatic ductal adenocarcinoma progression by regulating the miR-411-3p/HIF-1α axis. Oncology Reports, 46(1). https://doi.org/10.3892/or.2021.8085

183.

Wang, S., You, H., & Yu, S. (2020). Long non-coding RNA HOXA-AS2 promotes the expression levels of hypoxia-inducible factor-1α and programmed death-ligand 1, and regulates nasopharyngeal carcinoma progression via miR-519. Oncology Letters, 20(5), 245. https://doi.org/10.3892/ol.2020.12107CrossRefPubMedPubMedCentral

184.

Zhao, R., Sun, F., Bei, X., Wang, X., Zhu, Y., Jiang, C., et al. (2017). Upregulation of the long non-coding RNA FALEC promotes proliferation and migration of prostate cancer cell lines and predicts prognosis of PCa patients. Prostate, 77(10), 1107–1117. https://doi.org/10.1002/pros.23367CrossRefPubMed

185.

Liu, L., Zhao, X., Zou, H., Bai, R., Yang, K., & Tian, Z. (2016). Hypoxia Promotes Gastric Cancer Malignancy Partly through the HIF-1α Dependent Transcriptional Activation of the Long Non-coding RNA GAPLINC. Frontiers in Physiology, 7, 420. https://doi.org/10.3389/fphys.2016.00420CrossRefPubMedPubMedCentral

186.

Liu, J., Liu, H., Zeng, Q., Xu, P., Liu, M., & Yang, N. (2020). Circular RNA circ-MAT2B facilitates glycolysis and growth of gastric cancer through regulating the miR-515-5p/HIF-1α axis. Cancer Cell International, 20, 171. https://doi.org/10.1186/s12935-020-01256-1CrossRefPubMedPubMedCentral

187.

Zhao, J. P., & Chen, L. L. (2020). Circular RNA MAT2B Induces Colorectal Cancer Proliferation via Sponging miR-610, Resulting in an Increased E2F1 Expression. Cancer Management and Research, 12, 7107–7116. https://doi.org/10.2147/cmar.S251180CrossRefPubMedPubMedCentral

188.

Wang, H., Feng, L., Cheng, D., Zheng, Y., Xie, Y., & Fu, B. (2021). Circular RNA MAT2B promotes migration, invasion and epithelial-mesenchymal transition of non-small cell lung cancer cells by sponging miR-431. Cell Cycle, 20(16), 1617–1627. https://doi.org/10.1080/15384101.2021.1956106CrossRefPubMedPubMedCentral

189.

Liu, A., & Xu, J. (2021). Circ_03955 promotes pancreatic cancer tumorigenesis and Warburg effect by targeting the miR-3662/HIF-1α axis. Clinical & Translational Oncology, 23(9), 1905–1914. https://doi.org/10.1007/s12094-021-02599-5CrossRef

190.

Liu, Z., Zhou, Y., Liang, G., Ling, Y., Tan, W., Tan, L., et al. (2019). Circular RNA hsa_circ_001783 regulates breast cancer progression via sponging miR-200c-3p. Cell Death & Disease, 10(2), 55. https://doi.org/10.1038/s41419-018-1287-1CrossRef

191.

Dong, L., Zhang, L., Liu, H., Xie, M., Gao, J., Zhou, X., et al. (2020). Circ_0007331 knock-down suppresses the progression of endometriosis via miR-200c-3p/HiF-1α axis. Journal of Cellular and Molecular Medicine, 24(21), 12656–12666. https://doi.org/10.1111/jcmm.15833CrossRefPubMedPubMedCentral

192.

Jiang, Y., Ji, X., Liu, K., Shi, Y., Wang, C., Li, Y., et al. (2020). Exosomal miR-200c-3p negatively regulates the migraion and invasion of lipopolysaccharide (LPS)-stimulated colorectal cancer (CRC). BMC Mol Cell Biol, 21(1), 48. https://doi.org/10.1186/s12860-020-00291-0CrossRefPubMedPubMedCentral

193.

Anastasiadou, E., Messina, E., Sanavia, T., Mundo, L., Farinella, F., Lazzi, S., et al. (2021). MiR-200c-3p Contrasts PD-L1 Induction by Combinatorial Therapies and Slows Proliferation of Epithelial Ovarian Cancer through Downregulation of β-Catenin and c-Myc. Cells, 10(3). https://doi.org/10.3390/cells10030519

194.

Cao, L., Wang, M., Dong, Y., Xu, B., Chen, J., Ding, Y., et al. (2020). Circular RNA circRNF20 promotes breast cancer tumorigenesis and Warburg effect through miR-487a/HIF-1α/HK2. Cell Death & Disease, 11(2), 145. https://doi.org/10.1038/s41419-020-2336-0CrossRef

195.

Zhai, Z., Fu, Q., Liu, C., Zhang, X., Jia, P., Xia, P., et al. (2019). Emerging Roles Of hsa-circ-0046600 Targeting The miR-640/HIF-1α Signalling Pathway In The Progression Of HCC. Oncotargets and Therapy, 12, 9291–9302. https://doi.org/10.2147/ott.S229514CrossRefPubMedPubMedCentral

196.

Liu, J., Liu, Y., Zhang, Y., Zheng, J., Wang, S., & Cao, G. (2022). Circular RNA hsa_circ_0004543 Aggravates Cervical Cancer Development by Sponging MicroRNA hsa-miR-217 to Upregulate Hypoxia-Inducible Factor. Journal of Oncology, 2022, 4031403. https://doi.org/10.1155/2022/4031403CrossRefPubMedPubMedCentral

197.

Chi, Y., Luo, Q., Song, Y., Yang, F., Wang, Y., Jin, M., et al. (2019). Circular RNA circPIP5K1A promotes non-small cell lung cancer proliferation and metastasis through miR-600/HIF-1α regulation. Journal of Cellular Biochemistry, 120(11), 19019–19030. https://doi.org/10.1002/jcb.29225CrossRefPubMed

198.

Qian, W., Huang, T., & Feng, W. (2020). Circular RNA HIPK3 Promotes EMT of Cervical Cancer Through Sponging miR-338-3p to Up-Regulate HIF-1α. Cancer Management and Research, 12, 177–187. https://doi.org/10.2147/cmar.s232235CrossRefPubMedPubMedCentral

199.

Chen, L.-Y., Wang, L., Ren, Y.-X., Pang, Z., Liu, Y., Sun, X.-D., et al. (2020). The circular RNA circ-ERBIN promotes growth and metastasis of colorectal cancer by miR-125a-5p and miR-138-5p/4EBP-1 mediated cap-independent HIF-1α translation. Molecular Cancer, 19(1), 164. https://doi.org/10.1186/s12943-020-01272-9CrossRefPubMedPubMedCentral

200.

Xu, G., Li, M., Wu, J., Qin, C., Tao, Y., & He, H. (2020). Circular RNA circNRIP1 Sponges microRNA-138-5p to Maintain Hypoxia-Induced Resistance to 5-Fluorouracil Through HIF-1α-Dependent Glucose Metabolism in Gastric Carcinoma. Cancer Management and Research, 12, 2789–2802. https://doi.org/10.2147/cmar.s246272CrossRefPubMedPubMedCentral

201.

Zeng, Z., Zhao, Y., Chen, Q., Zhu, S., Niu, Y., Ye, Z., et al. (2021). Hypoxic exosomal HIF-1α-stabilizing circZNF91 promotes chemoresistance of normoxic pancreatic cancer cells via enhancing glycolysis. Oncogene, 40(36), 5505–5517. https://doi.org/10.1038/s41388-021-01960-wCrossRefPubMed

202.

Joo, H. Y., Yun, M., Jeong, J., Park, E. R., Shin, H. J., Woo, S. R., et al. (2015). SIRT1 deacetylates and stabilizes hypoxia-inducible factor-1α (HIF-1α) via direct interactions during hypoxia. Biochemical and Biophysical Research Communications, 462(4), 294–300. https://doi.org/10.1016/j.bbrc.2015.04.119CrossRefPubMed

203.

Shangguan, H., Feng, H., Lv, D., Wang, J., Tian, T., & Wang, X. (2020). Circular RNA circSLC25A16 contributes to the glycolysis of non-small-cell lung cancer through epigenetic modification. Cell Death & Disease, 11(6), 437. https://doi.org/10.1038/s41419-020-2635-5CrossRef

204.

Zhou, P., Xie, W., Huang, H. L., Huang, R. Q., Tian, C., Zhu, H. B., et al. (2020). circRNA_100859 functions as an oncogene in colon cancer by sponging the miR-217-HIF-1α pathway. Aging, 12(13), 13338–13353. https://doi.org/10.18632/aging.103438CrossRefPubMedPubMedCentral

205.

Feng, J., Yang, M., Wei, Q., Song, F., Zhang, Y., Wang, X., et al. (2020). Novel evidence for oncogenic piRNA-823 as a promising prognostic biomarker and a potential therapeutic target in colorectal cancer. Journal of Cellular and Molecular Medicine, 24(16), 9028–9040. https://doi.org/10.1111/jcmm.15537CrossRefPubMedPubMedCentral

206.

Tao, E.-W., Wang, H.-L., Cheng, W. Y., Liu, Q.-Q., Chen, Y.-X., & Gao, Q.-Y. (2021). A specific tRNA half, 5’tiRNA-His-GTG, responds to hypoxia via the HIF1α/ANG axis and promotes colorectal cancer progression by regulating LATS2. Journal of Experimental & Clinical Cancer Research, 40(1), 67. https://doi.org/10.1186/s13046-021-01836-7CrossRef

207.

Hong, D. S., Kang, Y.-K., Borad, M., Sachdev, J., Ejadi, S., Lim, H. Y., et al. (2020). Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours. British Journal of Cancer, 122(11), 1630–1637. https://doi.org/10.1038/s41416-020-0802-1CrossRefPubMedPubMedCentral

208.

Anastasiadou, E., Seto, A. G., Beatty, X., Hermreck, M., Gilles, M.-E., Stroopinsky, D., et al. (2021). Cobomarsen, an Oligonucleotide Inhibitor of miR-155, Slows DLBCL Tumor Cell Growth In Vitro and In Vivo. Clinical Cancer Research, 27(4), 1139–1149. https://doi.org/10.1158/1078-0432.ccr-20-3139CrossRefPubMed

209.

Reid, G., Pel, M. E., Kirschner, M. B., Cheng, Y. Y., Mugridge, N., Weiss, J., et al. (2013). Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma. Annals of Oncology, 24(12), 3128–3135. https://doi.org/10.1093/annonc/mdt412CrossRefPubMed

210.

Ronnen, E. A., Kondagunta, G. V., Ishill, N., Sweeney, S. M., Deluca, J. K., Schwartz, L., et al. (2006). A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma. Investigational New Drugs, 24(6), 543–546. https://doi.org/10.1007/s10637-006-9208-zCrossRefPubMed

211.

Yong, L., Tang, S., Yu, H., Zhang, H., Zhang, Y., Wan, Y., et al. (2022). The role of hypoxia-inducible factor-1 alpha in multidrug-resistant breast cancer. Frontiers in Oncology, 12, 964934. https://doi.org/10.3389/fonc.2022.964934CrossRefPubMedPubMedCentral

Titel: The strict regulation of HIF-1α by non-coding RNAs: new insight towards proliferation, metastasis, and therapeutic resistance strategies
verfasst von: Sabrean Farhan Jawad
Farag M. A. Altalbawy
Radhwan M. Hussein
Ali Abdulhussain Fadhil
Mohammed Abed Jawad
Rahman S. Zabibah
Tasneem Younus Taraki
Chakrabhavi Dhananjaya Mohan
Kanchugarakoppal S. Rangappa
Publikationsdatum: 08.08.2023
Verlag: Springer US
Erschienen in: Cancer and Metastasis Reviews / Ausgabe 1/2024
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-023-10129-8

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

The strict regulation of HIF-1α by non-coding RNAs: new insight towards proliferation, metastasis, and therapeutic resistance strategies

Abstract

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2024

Lipid metabolism and its implications in tumor cell plasticity and drug resistance: what we learned thus far?

Cancer cell plasticity: from cellular, molecular, and genetic mechanisms to tumor heterogeneity and drug resistance

Sam68 is a druggable vulnerability point in cancer stem cells

Harnessing function of EMT in cancer drug resistance: a metastasis regulator determines chemotherapy response

Modulation of hypoxia-inducible factor-1 signaling pathways in cancer angiogenesis, invasion, and metastasis by natural compounds: a comprehensive and critical review

Molecular panorama of therapy resistance in prostate cancer: a pre-clinical and bioinformatics analysis for clinical translation

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie